Skip to the answer

Canagliflozin

Canagliflozin is a once-daily SGLT2 inhibitor used to lower blood sugar in type 2 diabetes and to reduce heart and kidney risks in certain adults with type 2 diabetes.

Brand name Invokana
Drug classes P-glycoprotein Inhibitors
Rx Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 5 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 5, 2026
Canagliflozin at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Canagliflozin (Invokana), on the market since about 2013, treats type 2 diabetes by making the kidneys flush extra sugar into the urine; a common add-on to metformin, it also lowers the risk of heart attack, stroke, kidney failure and heart failure hospitalization in certain adults. Most people tolerate it well, noticing mainly more urination and thirst, though genital yeast and urinary infections are common. Watch hardest for ketoacidosis (a dangerous acid buildup in the blood), even when sugar is not very high; nausea, vomiting, stomach pain or unusual tiredness means stop it and get help. Stay hydrated and report foot sores early, since dehydration and amputation are real risks.

Clinical pearls

  • Take it before the first meal of the day, which also keeps the extra urination from interrupting your sleep.
  • Tell any surgeon you take it, and ask about sick days, since fasting, illness and surgery all raise ketoacidosis risk.
  • If you also use insulin or a sulfonylurea like glipizide, those doses may need lowering to prevent low blood sugar.
  • Urine glucose strips will read positive and 1,5-AG blood tests become unreliable, so track sugar with a meter or A1C.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asTablet
Earliest FDA record2013
Companies listing it with the FDA3
FDA label last updatedFeb 17, 2026
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Canagliflozin, written from its FDA label.

What Canagliflozin is used for

▾

Canagliflozin is used in type 2 diabetes. These uses apply to Invokana tablets:

  • With diet and exercise, to improve blood sugar control in adults and children aged 10 and older with type 2 diabetes.
  • To reduce the risk of cardiovascular death, nonfatal heart attack and nonfatal stroke in adults with type 2 diabetes and established cardiovascular disease.
  • To reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes and diabetic nephropathy with albuminuria.
  • It is not recommended for blood sugar control in type 1 diabetes, or in type 2 diabetes with eGFR below 30.

How Canagliflozin works

▾

Canagliflozin blocks SGLT2, a protein in the kidneys that reabsorbs most of the sugar filtered from your blood. Blocking it lets more sugar leave in your urine, which lowers blood sugar.

It also increases sodium delivery to a later part of the kidney's tubes. This is believed to reduce pressure inside the kidney's filters.

Canagliflozin dosage

▾

Invokana is a once-daily tablet taken by mouth. For blood sugar control, take it before the first meal of the day. Food does not change how much of it your body absorbs.

  • Your prescriber sets the dose based on your condition, kidney function and other medicines.
  • If you miss a dose, take it as soon as possible. Do not double the next dose.
  • Kidney function and hydration are checked before starting.

Dosing details from the FDA-approved label

From the Canagliflozin prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus
    • Starting dosage 100 mg orally once daily, taken before the first meal of the day
    • May be increased to 300 mg once daily in patients tolerating 100 mg once daily who have an eGFR of 60 mL/min/1.73 m2 or greater and require additional glycemic control
    • Maximum: 300 mg once daily
    • Assess renal function and correct volume depletion before initiating
  • Reduce risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease
    • 100 mg orally once daily
  • Reduce risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day
    • 100 mg orally once daily
    • Adults with albuminuria greater than 300 mg/day may continue 100 mg once daily with renal impairment
  • Renal impairment, eGFR 30 to less than 60 mL/min/1.73 m2 (adults and pediatric patients aged 10 years and older)
    • Maximum recommended dosage is 100 mg orally once daily
    • Maximum: 100 mg once daily
    • Based on eGFR
  • Renal impairment, eGFR less than 30 mL/min/1.73 m2
    • Initiation is not recommended
    • Adults with albuminuria greater than 300 mg/day may continue 100 mg once daily
  • Concomitant UGT enzyme inducer (e.g., rifampin, phenytoin, phenobarbital, ritonavir) with eGFR 60 mL/min/1.73 m2 or greater
    • Increase to 200 mg orally once daily in patients currently tolerating 100 mg once daily
    • Maximum: 300 mg once daily
    • Dosage increase based on renal function
  • Concomitant UGT enzyme inducer with eGFR less than 60 mL/min/1.73 m2
    • Increase to 200 mg orally once daily in patients currently tolerating 100 mg once daily
    • Maximum: 200 mg once daily
    • Dosage increase based on renal function
  • Surgery or procedures associated with prolonged fasting
    • Withhold at least 3 days, if possible, prior to surgery or procedure
    • Resume when patient is clinically stable and has resumed oral intake
  • Missed dose
    • Take the dose as soon as possible
    • Do not double up the next dose
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Assess renal function before initiating and as clinically indicated. Assess volume status and correct volume depletion before initiating ( 2.1 ). The recommended starting dosage in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus is 100 mg orally once daily, taken before the first meal of the day to improve glycemic control. The dosage can be increased to 300 mg once daily in patients tolerating 100 mg once daily who have an eGFR of 60 mL/min/1.73 m 2 or greater and require additional glycemic control ( 2.2 ). For all other indications in adults, the recommended dosage of INVOKANA is 100 mg orally once daily ( 2.2 ). Dosage adjustments for patients with renal impairment may be required ( 2.3 ). See full prescribing information for INVOKANA dosage modifications due to drug interactions ( 2.4 ). Withhold INVOKANA at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting ( 2.5 ). 2.1 Prior to Initiation of INVOKANA Assess renal function before initiating INVOKANA and as clinically indicated [see Dosage and Administration (2.3) and Warnings and Precautions (5.3) ] . In patients with volume depletion, correct this condition before initiating INVOKANA [see Warnings and Precautions (5.3) and Use in Specific Populations (8.5 , 8.6) ] . 2.2 Recommended Dosage and Administration Recommended Dosage for Glycemic Control in Adults and Pediatric Patients Aged 10 Years and Older The recommended starting dosage of INVOKANA is 100 mg orally once daily to improve glycemic control, taken before the first meal of the day. For additional glycemic control, the dosage of INVOKANA may be increased to the maximum recommended dosage of 300 mg once daily. Recommended Dosage for Other Indications in Adults The recommended dosage of INVOKANA is 100 mg orally once daily for the following indications in adults: to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Canagliflozin side effects

▾

Most side effects are related to extra sugar in the urine and fluid loss.

Common side effects

  • Female genital yeast infections
  • Male genital yeast infections (such as balanitis)
  • Urinary tract infections
  • Increased urination
  • Thirst or dry mouth
  • Constipation
  • Nausea
  • Vulvovaginal itching
  • Genital yeast infections in women and men
  • Abdominal pain, fatigue and falls were also reported

When to get medical help

  • Nausea, vomiting, stomach pain, unusual tiredness or shortness of breath may signal ketoacidosis. Stop the medicine and get medical help right away, even if your blood sugar is not very high.
  • Pain, tenderness, redness or swelling in the genital or area between the genitals and anus, with fever or feeling unwell, can be a rare, life-threatening infection (Fournier's gangrene). Seek care immediately.
  • New pain, sores, ulcers or infection in your legs or feet need prompt attention. Your doctor may stop the medicine.
  • Dizziness, fainting, or signs of dehydration may mean low fluid volume, which can harm the kidneys.
  • Signs of a serious urinary or kidney infection need prompt treatment.
  • Swelling of the face, lips or throat, or a severe rash or hives, may be a serious allergic reaction. Stop the medicine and get help.
  • Low blood sugar symptoms can happen, especially if you also take insulin or a sulfonylurea.

Seek medical help for signs of ketoacidosis, genital-area pain with fever, leg or foot sores, dehydration or fainting, serious infection, or allergic reaction.

Canagliflozin warnings and precautions

▾
  • Ketoacidosis: can be life-threatening and can occur with near-normal blood sugar. Watch for nausea, vomiting, stomach pain, unusual tiredness and shortness of breath.
  • Lower limb amputation: risk was higher in trials. Risk is highest with prior amputation, poor circulation or neuropathy. Do routine foot care.
  • Dehydration and kidney injury: more likely in older adults, those with kidney impairment, and those taking loop diuretics.
  • Serious infections: urinary infections (including kidney infection and urosepsis), genital yeast infections and Fournier's gangrene.
  • Low blood sugar: more likely with insulin or sulfonylureas.
  • Allergic reactions and bone fractures have been reported.

Canagliflozin interactions

▾

Several medicines can change how canagliflozin works or how other drugs behave with it.

  • Rifampin, phenytoin, phenobarbital, ritonavir: lower canagliflozin levels, so the dose may need to rise.
  • Insulin and sulfonylureas: higher risk of low blood sugar.
  • Digoxin: levels can increase.
  • Lithium: levels may decrease.
  • Loop diuretics: greater risk of fluid loss.
  • Urine glucose and 1,5-AG tests are not reliable for tracking blood sugar.

Interactions listed in the FDA-approved label

From the Canagliflozin prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • UGT enzyme inducers (rifampin, phenytoin, phenobarbital, ritonavir): UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. With eGFR 60 or greater, increase to 200 mg daily in patients tolerating 100 mg daily; may increase to 300 mg daily in patients tolerating 200 mg daily who require additional glycemic control. With eGFR less than 60, increase to 200 mg daily in patients tolerating 100 mg daily; consider adding another antihyperglycemic agent if additional glycemic control is
  • Insulin or insulin secretagogues (e.g., sulfonylurea): The risk of hypoglycemia is increased when INVOKANA is used concomitantly with insulin secretagogues or insulin. Concomitant use may require a lower dosage of the insulin secretagogue or insulin to reduce the risk of hypoglycemia.
  • Digoxin: Canagliflozin increases digoxin exposure. Monitor patients taking INVOKANA with concomitant digoxin for a need to adjust the dosage of digoxin.
  • Lithium: Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Monitor serum lithium concentration more frequently during INVOKANA initiation and dosage changes.
  • Urine glucose tests: SGLT2 inhibitors increase urinary glucose excretion which will lead to positive urine glucose tests. Monitoring glycemic control with urine glucose tests is not recommended; use alternative methods to monitor glycemic control.
  • 1,5-anhydroglucitol (1,5-AG) assay: Measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Monitoring glycemic control with 1,5-AG assay is not recommended; use alternative methods to monitor glycemic control.
Read the label’s full interactions text

7 DRUG INTERACTIONS Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. Intervention: For patients with eGFR 60 mL/min/1.73 m 2 or greater, if an inducer of UGTs is administered with INVOKANA, increase the dosage to 200 mg daily in patients currently tolerating INVOKANA 100 mg daily. The total daily dosage may be increased to 300 mg daily in patients currently tolerating INVOKANA 200 mg daily who require additional glycemic control. For patients with eGFR less than 60 mL/min/1.73 m 2 , if an inducer of UGTs is administered with INVOKANA, increase the dosage to 200 mg daily in patients currently tolerating INVOKANA 100 mg daily. Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . Examples: Rifampin, phenytoin, phenobarbital, ritonavir Insulin or Insulin Secretagogues Clinical Impact: The risk of hypoglycemia is increased when INVOKANA is used concomitantly with insulin secretagogues (e.g., sulfonylurea) or insulin. Intervention: Concomitant use may require a lower dosage of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. Digoxin Clinical Impact: Canagliflozin increases digoxin exposure [see Clinical Pharmacology (12.3) ] . Intervention: Monitor patients taking INVOKANA with concomitant digoxin for a need to adjust the dosage of digoxin. Lithium Clinical Impact: Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention: Monitor serum lithium concentration more frequently during INVOKANA initiation and dosage changes. Drug/Laboratory Test Interference Positive Urine Glucose Test Clinical Impact: SGLT2 inhibitors increase urinary glucose excretion which will lead to positive urine glucose tests.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿256 supplements and herbs with documented Canagliflozin interactions, ranked by severity Check Canagliflozin against a supplement or herb →

Before taking Canagliflozin

▾
  • Do not use after a serious allergic reaction to Invokana.
  • Not for improving blood sugar in type 1 diabetes.
  • Kidney impairment: dose limits apply, and starting it is not recommended if eGFR is below 30 for blood sugar control.
  • Older adults have more fluid-loss side effects.
  • Not recommended in the second and third trimesters of pregnancy or while breastfeeding.
  • Not recommended in severe liver impairment.
  • Approved for blood sugar control in children aged 10 and older. Safety for heart or kidney uses in children has not been established.

Canagliflozin overdose

▾

If you take too much, call Poison Help at 1-800-222-1222 or seek medical help. Care is supportive, with clinical monitoring. Dialysis removes very little canagliflozin.

What Canagliflozin does in the body

▾

Canagliflozin lowers the kidney's sugar threshold, so more sugar passes into the urine, about 100 grams a day in studies of people with type 2 diabetes. Blood sugar began falling within the first day. The extra urine sugar fades back toward normal about 3 days after stopping. In a study, it also did not meaningfully change the heart's QTc interval.

How your body processes Canagliflozin

▾

Peak blood levels occur about 1 to 2 hours after a dose. The half-life is about 10.6 to 13.1 hours, and steady levels are reached in 4 to 5 days of daily dosing. Food does not change absorption. It is mainly broken down by the liver into inactive products, and is cleared in the feces and urine, with very little leaving unchanged in urine.

How to store Canagliflozin

▾

Keep out of reach of children. Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted between 15 °C to 30 °C (59 °F to 86 °F) .

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

256

Supplements & herbs that interact with Canagliflozin

256 supplements and herbal products have documented interactions with Canagliflozin in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 2
  • Moderate · 215
  • Minor · 39
ACTIVATED CHARCOAL Major SIBERIAN COCKLEBUR Major ACAI Moderate AFRICAN WILD POTATO Moderate AGARICUS MUSHROOM Moderate AGMATINE Moderate AGRIMONY Moderate ALFALFA Moderate +248 more
Every supplement checked against Canagliflozin — ranked by severity The full interaction hub: 2 major · 215 moderate · 39 minor · every one linked to its full report. Check Canagliflozin against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

1

Nutrient depletion considerations

Canagliflozin has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.

COENZYME Q10 Insignificant Depletion
See the full Canagliflozin nutrient depletion report

Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.

Canagliflozin: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Canagliflozin — the kind of thing our pharmacy team would talk through with you at the counter.

What is canagliflozin for?

▾
It helps control blood sugar in type 2 diabetes, in adults and children 10 and older, along with diet and exercise. In adults, it also lowers the risk of cardiovascular events if you have established cardiovascular disease. It also lowers kidney and heart failure risks if you have diabetic kidney disease with heavy protein in your urine.

How do I take it?

▾
Take your Invokana tablet by mouth once a day, ideally before your first meal. You can take it with or without food. If you miss a dose, take it when you remember, but never double up.

What side effects should I expect?

▾
Because it sends sugar out through your urine, you may urinate more and feel thirsty. Genital yeast infections and urinary tract infections are common. Good hygiene and telling your doctor early about itching, discharge or burning can help.

When should I call my doctor or get urgent help?

▾
Get help right away for nausea, vomiting, stomach pain, unusual tiredness or trouble breathing, even if your sugar looks fine. Also seek help for pain, redness or swelling in the genital area with fever, or swelling of the face or throat. Report any new foot or leg sores, or fainting and dehydration.

Does it interact with my other medicines?

▾
It can. Insulin and sulfonylureas may need lower doses to avoid low blood sugar. Medicines like rifampin, phenytoin, phenobarbital and ritonavir can lower its effect. Digoxin and lithium levels may need monitoring, so tell me about everything you take.

Can I take it if I'm pregnant or breastfeeding?

▾
It is not recommended in the second and third trimesters of pregnancy, or while breastfeeding, because of possible effects on a baby's developing kidneys. Talk to your doctor if you are pregnant or planning to be.

Is Canagliflozin available over the counter?

▾
No. Canagliflozin is a prescription medicine: every Canagliflozin product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Canagliflozin first available?

▾
The earliest FDA record we hold for Canagliflozin is from 2013: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Canagliflozin was first used.

Who makes Canagliflozin?

▾
3 companies currently list Canagliflozin products in the FDA's NDC Directory, including A-S Medication Solutions, Cardinal Health 107, LLC, Janssen Pharmaceuticals, Inc.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Canagliflozin on HelloPharmacist

📊Canagliflozin supplement interactions256 checked — ranked by severity 🌿Drug & Supplement CheckerCanagliflozin vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Canagliflozin NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Canagliflozin Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Canagliflozin forms and strengths (how it comes)

Canagliflozin is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Tablet

By mouth
Brands Invokana
How this form is used
What it may be used for
  • Invokana is used with diet and exercise to improve blood sugar control in adults and children aged 10 and older with type 2 diabetes.
  • Invokana is used to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
  • Invokana is used to reduce the risk of end-stage kidney disease, cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes and diabetic nephropathy with albuminuria.
Important instructions
  • Invokana is taken by mouth once daily, and for blood sugar control it is recommended before the first meal of the day.
  • Invokana may be taken with or without food.
  • If you miss a dose of Invokana, take it as soon as possible, and do not double up the next dose.
  • Invokana is usually held at least 3 days before surgery or procedures with prolonged fasting, if possible.
Available strengths 2 strengths
100 mg 300 mg
21 FDA-listed product records ⓘ

Canagliflozin on the U.S. market: products, makers and brands

How Canagliflozin appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

3 companies list 7 Canagliflozin product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2013. Brand names on the directory include Invokana; the rest are generics.

1
Dose forms ⓘ
3
Labelers (makers, repackagers, distributors)
1
Brand names
7
FDA-listed product records ⓘ
2013
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Powder (13) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

A-S Medication Solutions43%
Cardinal Health 107, LLC29%
Janssen Pharmaceuticals, Inc.29%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Canagliflozin is used (Medicaid data)

A general measure of how commonly Canagliflozin is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Canagliflozin is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

60,010
Medicaid prescriptions filled (Q1–Q4 2025)
$48.9M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Canagliflozin prescribed? Of the 1,601 medications we measure, Canagliflozin ranks #600 by Medicaid prescriptions — more than 63% of them.

Where Canagliflozin ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #600 of 1,601
#595 Dextromethorphan 60,739 Rx #596 Amlodipine / Olmesarta... 60,729 Rx #597 Piperacillin and Tazob... 60,527 Rx #598 Piperacillin / Tazobac... 60,527 Rx #599 Cabotegravir / Rilpivi... 60,221 Rx #600 Canagliflozin 60,010 Rx #601 Miconazole Topical 59,616 Rx #602 Deutetrabenazine 59,566 Rx #603 Linagliptin / Metformi... 59,483 Rx #604 Imipramine 59,329 Rx #605 Nadolol 59,132 Rx

Utilization by Canagliflozin product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 300 mg oral tablet is the most-dispensed Canagliflozin product — about 59% of these Medicaid prescriptions.

canagliflozin 300 MG Oral Tablet Most dispensed

35,237 Medicaid prescriptions (Q1–Q4 2025) 59% of Canagliflozin prescriptions shown $28.6M gross reimbursement (before rebates) ≈ $811 per prescription (gross)

Summed across the 2 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1373471

canagliflozin 100 MG Oral Tablet

24,773 Medicaid prescriptions (Q1–Q4 2025) 41% of Canagliflozin prescriptions shown $20.4M gross reimbursement (before rebates) ≈ $823 per prescription (gross)

Summed across the 2 of 11 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1373463

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Canagliflozin, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 4 of 20 listed Canagliflozin NDCs with Medicaid activity.

Compare Canagliflozin products

A representative set of FDA-listed product records for Canagliflozin — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Tablet
100 mg Oral A-S Medication Solutions NDA View NDC →
300 mg Oral A-S Medication Solutions × 2 listings NDA View NDC →
100 mg Oral Cardinal Health 107, LLC NDA View NDC →
300 mg Oral Cardinal Health 107, LLC NDA View NDC →
100 mg Oral Janssen Pharmaceuticals, Inc. NDA View NDC →
300 mg Oral Janssen Pharmaceuticals, Inc. NDA View NDC →

Showing 7 of 7 products — FDA National Drug Code Directory. See every product, package size and price: browse all 7 Canagliflozin NDCs →

Canagliflozin recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Canagliflozin recalls since July 2021.

✅No Canagliflozin recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Canagliflozin RxCUI 1373458 1 dose form · 2 strengths
  1. Dose form (SCDF) Oral Tablet RxCUI 1373462 In current FDA listings
    Clinical drug / strength (SCD) 100 MG RxCUI 1373463 300 MG RxCUI 1373471

Look up RxCUI 1373458 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Canagliflozin brand names

Canagliflozin is sold under one brand name in the FDA directory — Invokana. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Invokana

Who makes Canagliflozin: manufacturers and labelers

3 companies list Canagliflozin products with the FDA. By number of product records, the largest are A-S Medication Solutions, Cardinal Health 107, LLC, Janssen Pharmaceuticals, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

A-S Medication Solutions 3 Cardinal Health 107, LLC 2 Janssen Pharmaceuticals, Inc. 2

Canagliflozin drug class (RxNorm)

Canagliflozin belongs to the Sodium-Glucose Cotransporter 2 Inhibitor class.

Pharmacologic class Sodium-Glucose Cotransporter 2 Inhibitor
Drug family (ATC) Sodium-glucose co-transporter 2 (SGLT2) inhibitors
How it works P-Glycoprotein Inhibitors, Sodium-Glucose Transporter 2 Inhibitors

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Canagliflozin page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Feb 17, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Canagliflozin.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Canagliflozin after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
5
Finished products in the current FDA directory
7
Companies listing them (makers, repackagers, distributors)
3
FDA labeler codes behind them ⓘ
3
Linked representative label ⓘ
Cardinal Health
Linked label effective
Feb 17, 2026
Composite sections available
23
Linked SPL Set ID
5f76e16f-0c24-454a-81af-4080b312c940
Linked SPL Document ID
aad6a5e4-0449-44dd-8bb7-e9b17a1fbbc3
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Cardinal Health is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →